Ivenix Wins Fierce Innovation Awards for Drug Delivery Technology and Best New Product
- Boston, December 13, 2021 – Ivenix Inc., a medical technology company with the vision to eliminate infusion-related patient harm, today announced it has been awarded the Fierce Innovation Life Science Awards for Technology Innovation in Drug Delivery Technology and Best New Product or Service from Fierce Life Sciences. This independent market intelligence publication identifies and showcases outstanding innovation driving improvements and transforming the industry….READ MORE
Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
- Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
- Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s (exploratory phase IIa) and neuropathic pain (phase I)
- Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones
Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE
Prealize Launches 2022 State of Health Market Report - The Domino Effect
PALO ALTO, Calif., Jan. 5, 2022 /PRNewswire/ — Prealize, an artificial intelligence (AI)-enabled predictive analytics company, today announced the release of its second annual State of Health Report. This year’s report explores key medical conditions that payers and healthcare providers should proactively address in 2022… READ MORE
Teladoc Health Launches “myStrength Complete” As First Unified Mental Health Care Experience
New Consumer Study Reinforces Impact of Comprehensive Virtual Mental Health Care
PURCHASE, NY May 11, 2021 — Teladoc Health, Inc. (NYSE: TDOC) today announced the launch of myStrength Complete, an integrated mental health service providing personalized, targeted care to consumers in a single, comprehensive experience. The announcement comes as more than half of people with mental health concerns report that they do not know where to start when getting care, highlighting the importance of the digital front door myStrength Complete will provide.…READ MORE
Sapphire Digital, now part of Zelis, is a mission-driven company that drives competition in healthcare to lower cost and improve quality for all
Bayer AG Completes its Acquisition of Vividion Therapeutics
SAN DIEGO – August 19, 2021 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Bayer AG has completed its acquisition of Vividion Therapeutics, Inc., Percival has been appointed as head of regulatory…READ MORE
Privia Health Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ARLINGTON, VA.- May 3, 2021– Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, announced the closing of its initial public offering of 22,425,000 shares of its common stock at a public offering price of $23.00 per share. The offering consisted of 5,725,000 shares of common stock offered by Privia Health and 16,700,000 shares of common stock sold by Privia Health’s majority stockholder…READ MORE